Marius holds an Orphan Designation for the treatment of Constitutional Delay in Growth and Puberty (CDGP) which affects over 100,000 boys in the US every year. Marius is developing its lead formulation to also address this crucial, unmet need for the youth population.
Key Benefits of Our Solution for CDGP:
Simple Oral Delivery
Advantageous Release Profile
Positive Efficacy & Safety Profile
Marius is also looking to address Klinefelter's syndrome with Phase II Studies planned.